{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:31:22Z","timestamp":1769603482172,"version":"3.49.0"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: Precise and comprehensive analysis of neuroblastoma genetics is essential for accurate risk evaluation and only pangenomic\/multilocus approaches fulfill the present-day requirements. We present the establishment and validation of the PCR-based multiplex ligation-dependent probe amplification (MLPA) technique for neuroblastoma.<\/jats:p>\n               <jats:p>Experimental Design: A neuroblastoma-specific MLPA kit was designed by the SIOP Europe Neuroblastoma Biology Committee in cooperation with MRC-Holland. The contained target sequences cover 19 chromosomal arms and reference loci. Validation was performed by single locus and pangenomic techniques (n = 174). Dilution experiments for determination of minimal tumor cell percentage were performed and testing of reproducibility was checked by interlaboratory testing (n = 15). Further 156 neuroblastomas were used for establishing the amplification cutoff level.<\/jats:p>\n               <jats:p>Results: The MLPA technique was tested in 310 neuroblastomas and 8 neuroblastoma cell lines (including validation and amplification cutoff level testing). Intertechnique validation showed a high concordance rate (99.5%). Interlaboratory MLPA testing (\u03ba = 0.95, P &amp;lt; 0.01) revealed 7 discrepant of 1,490 results (0.5%). Validation by pangenomic techniques showed a single discordance of 190 consensus results (0.5%). The test results led to formulation of interpretation standards and to a kit revision. The minimal tumor cell percentage was fixed at 60%.<\/jats:p>\n               <jats:p>Conclusions: The recently designed neuroblastoma-specific MLPA kit covers all chromosomal regions demanded by the International Neuroblastoma Risk Group for therapy stratification and includes all hitherto described genetic loci of prognostic interest for future studies and can be modified or extended at any time. Moreover, the technique is cost effective, reliable, and robust with a high interlaboratory and intertechnique concordance. Clin Cancer Res; 17(4); 792\u2013804. \u00a92011 AACR.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-10-0830","type":"journal-article","created":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T22:18:35Z","timestamp":1297894715000},"page":"792-804","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma"],"prefix":"10.1158","volume":"17","author":[{"given":"Inge M.","family":"Ambros","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Bettina","family":"Brunner","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Gerhard","family":"Aigner","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Clare","family":"Bedwell","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Klaus","family":"Beiske","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Jean","family":"B\u00e9nard","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Nick","family":"Bown","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Valerie","family":"Combaret","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Jerome","family":"Couturier","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Raffaella","family":"Defferrari","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Nicole","family":"Gross","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Marta","family":"Jeison","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"John","family":"Lunec","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Barbara","family":"Marques","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Tommy","family":"Martinsson","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Katia","family":"Mazzocco","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Rosa","family":"Noguera","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Gudrun","family":"Schleiermacher","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Frank","family":"Speleman","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Ray","family":"Stallings","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Gian Paolo","family":"Tonini","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Deborah A.","family":"Tweddle","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Alexander","family":"Valent","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Ales","family":"Vicha","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Nadine Van","family":"Roy","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Eva","family":"Villamon","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Andrea","family":"Ziegler","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Sandra","family":"Preuner","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Mario","family":"Drobics","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Ruth","family":"Ladenstein","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Gabriele","family":"Amann","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Robert J.L.","family":"Schuit","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Ulrike","family":"P\u00f6tschger","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]},{"given":"Peter F.","family":"Ambros","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; 2Safety & Security Department, Information Management & eHealth, AIT Austrian Institute of Technology GmbH; 3St. Anna Kinderspital; and 4Institut f\u00fcr Klinische Pathologie, Universit\u00e4t Wien, Vienna, Austria; 5University of Newcastle upon Tyne; and 6Northern Institute for Cancer Research, Newcastle University, The Medical School, Newcastle upon Tyne, United Kingdom; 7Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 8D\u00e9partement de Biologie et de Pathologie m\u00e9dicales, Service de Pathologie Mol\u00e9culaire, Institut Gustave Roussy, Villejuif, France; 9Centre L\u00e9on B\u00e9rard, Laboratoire de Recherche Translationnelle, Lyon, France; 10Service de G\u00e9n\u00e9tique Oncologique\u2014Unite de Cytogenetique Institut Curie-\u2013Hopital; and 11Departement d'Oncologie Pediatrique, Institut Curie, Paris, France; 12Translational Paediatric Oncology, National Institute for Cancer Research, Genova, Italy;"}]}],"member":"1086","published-online":{"date-parts":[[2011,2,15]]},"reference":[{"key":"2022061019520486100_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022061019520486100_bib2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/sj.bjc.6605014","article-title":"International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee","volume":"100","author":"Ambros","year":"2009","journal-title":"Br J Cancer"},{"key":"2022061019520486100_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrc1014","article-title":"Neuroblastoma: biological insights into a clinical enigma","volume":"3","author":"Brodeur","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2022061019520486100_bib4","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.ejca.2004.07.025","article-title":"MYCN amplification remains prognostically strong 20 years after its \u201cclinical debut\u201d","volume":"40","author":"Cohn","year":"2004","journal-title":"Eur J Cancer"},{"key":"2022061019520486100_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.1991.9.4.581","article-title":"Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study","volume":"9","author":"Look","year":"1991","journal-title":"J Clin Oncol"},{"key":"2022061019520486100_bib6","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199606063342304","article-title":"Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma [see comments]","volume":"334","author":"Ambros","year":"1996","journal-title":"N Engl J Med"},{"key":"2022061019520486100_bib7","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2000.18.9.1888","article-title":"Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study","volume":"18","author":"Maris","year":"2000","journal-title":"J Clin Oncol"},{"key":"2022061019520486100_bib8","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJM199906243402504","article-title":"Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma [see comments]","volume":"340","author":"Bown","year":"1999","journal-title":"N Engl J Med"},{"key":"2022061019520486100_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.bjc.6603820","article-title":"Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification","volume":"97","author":"Schleiermacher","year":"2007","journal-title":"Br J Cancer"},{"key":"2022061019520486100_bib10","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2005.06.104","article-title":"Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma","volume":"23","author":"Vandesompele","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061019520486100_bib11","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMoa052399","article-title":"Chromosome 1p and 11q deletions and outcome in neuroblastoma","volume":"353","author":"Attiyeh","year":"2005","journal-title":"N Engl J Med"},{"key":"2022061019520486100_bib12","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1038\/sj.onc.1210552","article-title":"Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data","volume":"26","author":"Lastowska","year":"2007","journal-title":"Oncogene"},{"key":"2022061019520486100_bib13","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1200\/JCO.2008.16.0630","article-title":"Overall genomic pattern is a predictor of outcome in neuroblastoma","volume":"27","author":"Janoueix-Lerosey","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022061019520486100_bib14","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1093\/nar\/gnf056","article-title":"Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification","volume":"30","author":"Schouten","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"2022061019520486100_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2353\/jmoldx.2006.060012","article-title":"Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors","volume":"8","author":"Jeuken","year":"2006","journal-title":"J Mol Diagn"},{"key":"2022061019520486100_bib16","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1093\/nar\/6.10.3177","article-title":"Cloning of human satellite III DNA: different components are on different chromosomes","volume":"6","author":"Cooke","year":"1979","journal-title":"Nucleic Acids Res"},{"key":"2022061019520486100_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Psychol Meas"},{"key":"2022061019520486100_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1037\/h0031619","article-title":"Measuring scale agreement among many raters","volume":"76","author":"Fleiss","year":"1971","journal-title":"Psychol Bull"},{"key":"2022061019520486100_bib19","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/bioinformatics\/bti133","article-title":"Detection of low level genomic alterations by comparative genomic hybridization based on cDNA micro-arrays","volume":"21","author":"Bilke","year":"2005","journal-title":"Bioinformatics"},{"key":"2022061019520486100_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/gcc.20243","article-title":"Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH","volume":"44","author":"Selzer","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"2022061019520486100_bib21","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/gcc.20376","article-title":"Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome","volume":"45","author":"Spitz","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"2022061019520486100_bib22","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/gcc.20477","article-title":"Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression","volume":"46","author":"Mosse","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"2022061019520486100_bib23","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.1200\/JCO.2005.05.582","article-title":"Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study","volume":"23","author":"George","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061019520486100_bib24","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/gcc.20496","article-title":"ArrayCGH-based classification of neuroblastoma into genomic subgroups","volume":"46","author":"Michels","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"2022061019520486100_bib25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.onc.1210661","article-title":"Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature","volume":"27","author":"Tomioka","year":"2008","journal-title":"Oncogene"},{"key":"2022061019520486100_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1096-911X(20010101)36:1<1::AID-MPO1002>3.0.CO;2-L","article-title":"Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas","volume":"36","author":"Ambros","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"2022061019520486100_bib27","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-08-1648","article-title":"Heterogeneity of the MYCN oncogene in neuroblastoma","volume":"15","author":"Theissen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061019520486100_bib28","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1200\/JCO.2003.10.168","article-title":"Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors","volume":"21","author":"Kerbl","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022061019520486100_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00428-008-0633-6","article-title":"Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma","volume":"453","author":"Villamon","year":"2008","journal-title":"Virchows Arch"},{"key":"2022061019520486100_bib30","first-page":"165","article-title":"MLPA analysis of neuroblastoma tumours","volume":"15","author":"Elliot","year":"2007","journal-title":"Chromosome Res"},{"key":"2022061019520486100_bib31","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2003.03.025","article-title":"Quality assessment of genetic markers used for therapy stratification","volume":"21","author":"Ambros","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022061019520486100_bib32","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1158\/1078-0432.CCR-07-0573","article-title":"Combined 1p\/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?","volume":"13","author":"Weller","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022061019520486100_bib33","article-title":"ISCN (2005): an international system for human cytogenetic nomenclature","author":"Shaffer","year":"2005"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/17\/4\/792\/2002207\/792.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/17\/4\/792\/2002207\/792.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T22:23:43Z","timestamp":1654899823000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/17\/4\/792\/11940\/A-Multilocus-Technique-for-Risk-Evaluation-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,15]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,2,15]]},"published-print":{"date-parts":[[2011,2,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-10-0830","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,15]]}}}